Navigation Links
Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association

SUNNYVALE, Calif., May 22, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib (formerly, PCI-32765) have been selected for oral presentations at the 17th Congress of the European Hematology Association (EHA), June 14-17, 2012 in Amsterdam, The Netherlands.

The update on data presented specifically includes: 1) updated safety and efficacy data, including progression free survival, from the phase Ib/II CLL single agent trial in relapsed or refractory and treatment naive patients (PCYC-1102-CA); 2) safety and efficacy data from the phase Ib CLL combination trial with bendamustine and rituximab in relapsed or refractory patients (PCYC-1108-CA). Pharmacyclics plans to issue a material update on the ibrutinib clinical development program and its results in a press release after the EHA oral presentations.

Oral Presentation at EHA, Amsterdam, The Netherlands (June 14-17, 2012)
Date/Time: Saturday, June 16, 2012; 8:00 AM – 8:15 AM CET
Location: Elicium 1
Abstract # 1970: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) is Highly Active and Tolerable in Relapsed or Refractory and Treatment Naive Chronic Lymphocytic Leukemia Patients, Updated Results of a Phase Ib/II Study.
Dr. Susan M. O'Brien et al. MD Anderson Cancer Center, Houston, Texas.

Oral Presentation at EHA, Amsterdam, The Netherlands (June 14-17, 2012)
Date/Time: Saturday, June 16, 2012; 8:15 AM – 8:30 AM CET
Location: Elicium 1
Abstract # 1590: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study.
Dr. Jennifer Brown et al. Dana-Farber Cancer Institute, Boston, Massachusetts.

Ibrutinib is an oral first-in-class, selective, irreversible Bruton's tyrosine kinase (BTK) inhibitor being investigated for its potential in treating patients with chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B cell lymphoma, follicular lymphoma, and multiple myeloma, all of which are considered B-cell malignancies.  Ibrutinib is being jointly developed by Pharmacyclics, Inc. and Janssen Biotech, Inc.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics to Host a Conference Call on March 15, 2012 to Discuss Second Quarter Fiscal 2012 Financial and Operational Results
3. Pharmacyclics Inc. Receives Issue Notice of Significant Brutons Tyrosine Kinase (BTK) Patent
4. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
5. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
6. Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
7. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
8. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
9. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
10. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
11. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ) ... Administration of High Viscosity Drugs" report to ... announced the addition of the "Self Administration ... offering. --> Research and Markets ( ... "Self Administration of High Viscosity Drugs" ...
(Date:11/26/2015)... 26, 2015 ... "Radioimmunoassay Market by Type (Reagents & ... Academics, Clinical Diagnostic Labs), Application (Research, Clinical ... 2020" report to their offering. ... addition of the "Radioimmunoassay Market by ...
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government and UN ... African Centres of Excellence, and public R&D institutions, civil societies and other partners ... the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... ... 2015 , ... On November 25, 2015, officials of Narconon Arrowhead , ... release of a new cutting edge recovery program that has been 50 years in ... and alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative ...
(Date:11/25/2015)... ... ... On November 23rd 2015 Cozy Products, a division of Bird-X ... Products explains what this means for business moving forward. , The Tri Lite heater ... model: to sell personal heaters that reduce energy consumption, are economical and keep people ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Beddit® has ... Beddit Classic sleep tracking systems. The new app features a more intuitive SleepScoreā„¢ that ... understand how well you slept. The SleepScore is created by a proprietary algorithm. Beddit ...
Breaking Medicine News(10 mins):